Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xience is a family of drug-eluting coronary stent systems used in percutaneous coronary intervention (PCI) to treat coronary artery disease. The stents are made from medical-grade L-605 cobalt chromium alloy and are coated with a non-erodible polymer containing everolimus as the active drug. Everolimus is an mTOR inhibitor that suppresses neointimal hyperplasia by inhibiting smooth muscle cell proliferation and migration within the arterial wall. The polymer coating controls the release of everolimus into the vessel wall over time to reduce restenosis (re-narrowing) after stent placement. Multiple generations exist within the XIENCE family (e.g., XIENCE V™, PRIME™, Alpine™, Sierra™, Skypoint™), differing mainly in design features and deliverability but sharing core materials and mechanism[1][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xience.